Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116909 · ClinicalTrials.gov registry record · Phase 2
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
A Phase 2 study of Locally Recurrent or Metastatic Cancer of the Head and Neck and Must Have Failed First-Line Therapy, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 4
- Study locations
NCT00116909 is a Phase 2 study of Locally Recurrent or Metastatic Cancer of the Head and Neck and Must Have Failed First-Line Therapy that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 85 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT00116909, a Phase 2 study of Locally Recurrent or Metastatic Cancer of the Head and Neck and Must Have Failed First-Line Therapy, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
Conditions Studied
Interventions
- DRUG OSI 7904L
Study Locations (4)
Tennessee
- Sarah Cannon Cancer Center - Nashville
- The Vanderbilt Cancer Center - Nashville
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116909
The ClinicalTrials.gov registry entry for NCT00116909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Locally Recurrent or Metastatic Cancer of the Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which OSI 7904L is the first listed.
NCT00116909 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Tennessee, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00116909 about?
NCT00116909 is a clinical study titled "A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy". Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
What is the current status of trial NCT00116909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2004-08. Estimated completion is 2005-08.
What conditions does trial NCT00116909 study?
This clinical trial studies the following conditions: Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy.
What interventions are being tested in trial NCT00116909?
The interventions under investigation include: OSI 7904L (DRUG).
Who is sponsoring clinical trial NCT00116909?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00116909 being conducted?
This trial has 4 study locations across Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Locally Recurrent or Metastatic Cancer of the Head and Neck
All registered trials for this condition
Must Have Failed First-Line Therapy
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.